目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T5460 | COX | ||
Mofezolac 是一种非甾体类抗炎药,可缓解疼痛并具有抗炎活性,抑制 COX-1和COX-2的IC50为 1.44 和 447 nM。 | |||
T0649 | Apoptosis Mitophagy COX Endogenous Metabolite Autophagy | ||
Salicylic acid (2-Hydroxybenzoic acid) 是一种从柳树皮中提取的天然产物,是一种抗炎活性环加氧酶抑制剂,抑制COX-2活性。 | |||
T5759 | Lipoxygenase COX | ||
S-(+)-Marmesin (marmesin) 是一种从木橘成熟树皮中分离得到的香豆素,具有 COX-2/5-LOX 双重抑制活性。 | |||
T7838 | COX | ||
Losartan Carboxaldehyde 是氯沙坦的中间醛代谢产物。它不能阻断 AT1-R ,但可以抑制内皮环氧合酶 (COX)-2 的表达,起到抗炎作用。 | |||
T7540 | Calcium Channel Lipoxygenase COX | ||
2,5-Di-tert-butylhydroquinone (BHQ) 是一种有效和选择性的内质网 Ca2+-ATPase 抑制剂,可调节5-LO 以及COX-2活性,IC50分别为 1.8 和 14.1 μM。 | |||
T4643 | COX Endogenous Metabolite | ||
TFAP (N-(5-Aminopyridin-2-yl)-4-(trifluoromethyl)benzamide) 是环氧酶 1 的一种选择性抑制剂,IC50值为 0.8 μM。 | |||
T0784 | COX | ||
Tolfenamic Acid (GEA 6414) 是一种非甾体抗炎剂和抗癌剂,可用于治疗偏头痛的症状。它能选择性地抑制COX-2的活性,在 LPS 诱导的犬 DH82 单核细胞/巨噬细胞中,对COX-2的IC50值为 13.49 μM(3.53 μg/mL)。 | |||
T22368 | COX | ||
Metyrosine (α-Methyltyrosine) 是一种选择性酪氨酸羟化酶抑制剂,可显著抑制高 COX-2 活性和有效控制血压,具有抗炎和抗溃疡作用。 | |||
T2826 | COX | ||
Asaraldehyde (2,4,5-trimethoxy-Benzaldehyde) 是COX-2抑制剂,能够明显降低环加氧酶 II (COX-2) 的活性(IC50:100 μg/mL)。 | |||
T6568 | Apoptosis Lipoxygenase COX | ||
Licofelone (ML-3000) 是一种 COX/LOX 双重抑制剂,IC50分别为 0.21和0.18 μM,有潜力研究骨关节炎,具有抗炎和抗增殖作用。它可诱导细胞凋亡,减少促炎性白三烯和前列腺素的产生。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-01736 | COX-2 Protein, Human, Recombinant (His) | Human | Baculovirus Insect Cells | ||
PTGS2, also known as COX-2, is s component of Prostaglandin-endoperoxide synthase (PTGS). PTGS, also known as cyclooxygenase, is the key enzyme in prostaglandin biosynthesis, and acts both as a dioxygenase and as a peroxidase. There are two isozymes of PTGS: a constitutive PTGS1 and an inducible PTGS2, which differ in their regulation of expression and tissue distribution. PTGS2 is overexpressed in many cancers. The overexpression of PTGS2 along with increased angiogenesis and GLUT-1 expression is significantly associated with gallbladder carcinomas. Furthermore the product of COX-2, PGH2 is converted by prostaglandin E2 synthase into PGE2, which in turn can stimulate cancer progression. Consequently inhibiting COX-2 may have benefit in the prevention and treatment of these types of cancer. PTGS2 is regulated by specific stimulatory events, suggesting that it is responsible for the prostanoid biosynthesis involved in inflammation and mitogenesis. It mediates the formation of prostaglandins from arachidonate and may have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|